COVID-19 Critical Intelligence Unit

Daily evidence digest

22 February 2022

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Ivermectin treatment, paediatric hospitalisations and Omicron, risk of SARS-CoV-2 reinfection

Peer reviewed journals featured:

- Randomised controlled trial of ivermectin treatment in adults with mild to moderate COVID-19 and comorbidities (I-TECH trial) here
- Observational studies on:
 - o Paediatric COVID-19 hospitalisations during the first Omicron wave in South Africa here
 - Identifying COVID-19 multimorbidity profiles associated with severity <u>here</u>
 - o COVID-19 and symptoms of PTSD in family members after ICU discharge here
 - SARS-CoV-2 neutralising antibody levels in response to protein-, mRNA-, and vectorbased COVID-19 vaccines here

Letters and correspondence discussed:

- Decoupling of Omicron variant infections and severe COVID-19 here
- Long-term clinical outcomes of COVID-19 patients treated with imatinib <u>here</u>

Pre-peer review articles featured:

- Observational studies on:
 - o Risk of SARS-CoV-2 reinfection 18 months after primary infection here
 - Clinical severity of Omicron sub-lineage BA.2 compared to BA.1 in South Africa here
 - o COVID-19-related smell and taste impairment with Omicron variant here
 - Performance of three rapid antigen tests against the Omicron variant here
 - o Reliability of citations of medRxiv preprints in articles published on COVID-19 here
 - o Relative virulence of SARS-CoV-2 among vaccinated and unvaccinated individuals here
 - o Transmissibility of Omicron and Delta variants and the impact of vaccination here

Guidance and reports

- The World Health Organization published a manifesto for a healthy and green recovery from COVID-19 here
- Treatment updates from the National COVID-19 Clinical Evidence Taskforce <u>here</u>



News and blogs

- The impact of the pandemic on the mental health of children and young people here
- Antibodies after AstraZeneca and Pfizer vaccines decrease with age and are higher in women here

<u>Click here</u> to subscribe to the daily evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on <u>COVID-19 transmission</u>, SARS-CoV-2 <u>vaccines</u>, and <u>variants</u> of concern, <u>post-acute sequelae of COVID-19 (PASC)</u>, <u>surgery and COVID-19</u>, <u>rapid testing and risk mitigation strategies</u>.



The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.